Positive Trial Results For Keryx's Zerenex


Keryx Biopharmaceuticals Inc. (Nasdaq: KERX) reported positive results for a Phase 2 clinical trial of its end-stage renal disease treatment Zerenex. The stock price climbed 21 cents to $1.29.


About this Entry

This page contains a single entry by published on June 8, 2009 10:30 AM.

FDA Approves Angiotech's Pulmonary Embolism Device was the previous entry in this blog.

XOMA Presents New Upbeat Trial Results is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12